Daiichi Sankyo has begun marketing its single dose Inavir laninamivir octanoate DPI for the treatment of influenza in Japan. According to the company, it plans to supply a total of 4 million units for the 2010-2011 flu season. The product uses Hovione’s TwinCaps delivery system. Read the company’s press release.
